Gillian P. Bates - Publications

Affiliations: 
King's College London, London, UK 
Area:
Genetics, Huntington's disease

139 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Landles C, Milton RE, Ali N, Flomen R, Flower M, Schindler F, Gomez-Paredes C, Bondulich MK, Osborne GF, Goodwin D, Salsbury G, Benn CL, Sathasivam K, Smith EJ, Tabrizi SJ, ... ... Bates GP, et al. Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington'S Disease Model. Brain Communications. 2: fcaa066. PMID 32954323 DOI: 10.1093/braincomms/fcaa066  0.731
2020 Mason MA, Gomez-Paredes C, Sathasivam K, Neueder A, Papadopoulou AS, Bates GP. Silencing Srsf6 does not modulate incomplete splicing of the huntingtin gene in Huntington's disease models. Scientific Reports. 10: 14057. PMID 32820193 DOI: 10.1038/s41598-020-71111-w  0.405
2020 Hegde RN, Chiki A, Petricca L, Martufi P, Arbez N, Mouchiroud L, Auwerx J, Landles C, Bates GP, Singh-Bains MK, Dragunow M, Curtis MA, Faull RL, Ross CA, Caricasole A, et al. TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models. The Embo Journal. e104671. PMID 32757223 DOI: 10.15252/Embj.2020104671  0.362
2020 Ghosh R, Wood-Kaczmar A, Dobson L, Smith EJ, Sirinathsinghji EC, Kriston-Vizi J, Hargreaves IP, Heaton R, Herrmann F, Abramov AY, Lam AJ, Heales SJ, Ketteler R, Bates GP, Andre R, et al. Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 32329133 DOI: 10.1096/fj.201902277RR  0.35
2020 Nath SR, Lieberman ML, Yu Z, Marchioretti C, Jones ST, Danby ECE, Van Pelt KM, Sorarù G, Robins DM, Bates GP, Pennuto M, Lieberman AP. MEF2 impairment underlies skeletal muscle atrophy in polyglutamine disease. Acta Neuropathologica. PMID 32306066 DOI: 10.1007/s00401-020-02156-4  0.307
2019 Papadopoulou AS, Gomez-Paredes C, Mason MA, Taxy BA, Howland D, Bates GP. Extensive Expression Analysis of Htt Transcripts in Brain Regions from the zQ175 HD Mouse Model Using a QuantiGene Multiplex Assay. Scientific Reports. 9: 16137. PMID 31695145 DOI: 10.1038/s41598-019-52411-2  0.39
2019 Franich NR, Hickey MA, Zhu C, Osborne GF, Ali N, Chu T, Bove NH, Lemesre V, Lerner RP, Zeitlin SO, Howland D, Neueder A, Landles C, Bates GP, Chesselet MF. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene. Journal of Neuroscience Research. PMID 31282030 DOI: 10.1002/Jnr.24493  0.407
2019 Pido-Lopez J, Tanudjojo B, Farag S, Bondulich MK, Andre R, Tabrizi SJ, Bates GP. Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment. Scientific Reports. 9: 7202. PMID 31076648 DOI: 10.1038/s41598-019-43627-3  0.406
2019 Reindl W, Baldo B, Schulz J, Janack I, Lindner I, Kleinschmidt M, Sedaghat Y, Thiede C, Tillack K, Schmidt C, Cardaun I, Schwagarus T, Herrmann F, Hotze M, Osborne GF, ... ... Bates GP, et al. Meso scale discovery-based assays for the detection of aggregated huntingtin. Plos One. 14: e0213521. PMID 30913220 DOI: 10.1371/journal.pone.0213521  0.382
2018 Ast A, Buntru A, Schindler F, Hasenkopf R, Schulz A, Brusendorf L, Klockmeier K, Grelle G, McMahon B, Niederlechner H, Jansen I, Diez L, Edel J, Boeddrich A, Franklin SA, ... ... Bates GP, et al. mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease. Molecular Cell. 71: 675-688.e6. PMID 30193095 DOI: 10.1016/J.Molcel.2018.07.032  0.427
2018 Pido-Lopez J, Andre R, Benjamin AC, Ali N, Farag S, Tabrizi SJ, Bates GP. In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease. Scientific Reports. 8: 11447. PMID 30061661 DOI: 10.1038/s41598-018-29792-x  0.354
2017 Baron O, Boudi A, Dias C, Schilling M, Nölle A, Vizcay-Barrena G, Rattray I, Jungbluth H, Scheper W, Fleck RA, Bates GP, Fanto M. Stall in Canonical Autophagy-Lysosome Pathways Prompts Nucleophagy-Based Nuclear Breakdown in Neurodegeneration. Current Biology : Cb. 27: 3626-3642.e6. PMID 29174892 DOI: 10.1016/j.cub.2017.10.054  0.373
2017 Bondulich MK, Jolinon N, Osborne GF, Smith EJ, Rattray I, Neueder A, Sathasivam K, Ahmed M, Ali N, Benjamin AC, Chang X, Dick JRT, Ellis M, Franklin SA, Goodwin D, ... ... Bates GP, et al. Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice. Scientific Reports. 7: 14275. PMID 29079832 DOI: 10.1038/S41598-017-14290-3  0.345
2017 Bryant DT, Landles C, Papadopoulou AS, Benjamin AC, Duckworth JK, Rosahl T, Benn CL, Bates GP. Disruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice. Scientific Reports. 7: 11900. PMID 28928414 DOI: 10.1038/s41598-017-11630-1  0.677
2017 Neueder A, Landles C, Ghosh R, Howland D, Myers RH, Faull RLM, Tabrizi SJ, Bates GP. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients. Scientific Reports. 7: 1307. PMID 28465506 DOI: 10.1038/S41598-017-01510-Z  0.411
2016 Hjerpe R, Bett JS, Keuss MJ, Solovyova A, McWilliams TG, Johnson C, Sahu I, Varghese J, Wood N, Wightman M, Osborne G, Bates GP, Glickman MH, Trost M, Knebel A, et al. UBQLN2 Mediates Autophagy-Independent Protein Aggregate Clearance by the Proteasome. Cell. PMID 27477512 DOI: 10.1016/j.cell.2016.07.001  0.326
2016 Kakkar V, Månsson C, de Mattos EP, Bergink S, van der Zwaag M, van Waarde MA, Kloosterhuis NJ, Melki R, van Cruchten RT, Al-Karadaghi S, Arosio P, Dobson CM, Knowles TP, Bates GP, van Deursen JM, et al. The S/T-Rich Motif in the DNAJB6 Chaperone Delays Polyglutamine Aggregation and the Onset of Disease in a Mouse Model. Molecular Cell. PMID 27151442 DOI: 10.1016/J.Molcel.2016.03.017  0.358
2016 Tulino R, Benjamin AC, Jolinon N, Smith DL, Chini EN, Carnemolla A, Bates GP. Correction: SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice. Plos One. 11: e0150682. PMID 26919088 DOI: 10.1371/journal.pone.0150682  0.348
2016 Tulino R, Benjamin AC, Jolinon N, Smith DL, Chini EN, Carnemolla A, Bates GP. SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice. Plos One. 11: e0145425. PMID 26815359 DOI: 10.1371/journal.pone.0145425  0.399
2016 Wood-Kaczmar A, Ghosh R, Kriston-Vizi J, Smith EJ, Chadwick W, Hargreaves IP, Heales SJ, Abramov AY, Cole SL, Ketteler R, Bates GP, Andre R, Tabrizi SJ. B27 Abnormal bioenergetics in inclusion-containing mutant HTT exon 1 primary human neurons Journal of Neurology, Neurosurgery & Psychiatry. 87: A18.2-A19. DOI: 10.1136/jnnp-2016-314597.58  0.341
2016 Pido-Lopez J, Andre R, Benjamin A, Franklin SA, Tabrizi SJ, Bates GP. B24 Assessment of immune system activation status during the course of disease in huntington’s disease mouse model Journal of Neurology, Neurosurgery & Psychiatry. 87: A17.2-A17. DOI: 10.1136/jnnp-2016-314597.55  0.353
2016 Ghosh R, Wood-Kaczmar A, Andre R, Kriston-Vizi J, Ketteler R, Cole S, Smith EJ, Bates GP, Tabrizi SJ. B10 Inclusion formation in mutant HTT exon 1 expressing human neuronal cells Journal of Neurology, Neurosurgery & Psychiatry. 87: A12.2-A12. DOI: 10.1136/jnnp-2016-314597.41  0.306
2016 Bates GP, Osborne GF, Ali N, Benjamin AC, Papadopoulou AS, Howland D, Tabrizi SJ, Faull RL, Myers RH, Landles C, Neueder A. B4 Detection of the aberrantly spliced exon 1 – intron 1 htt mRNA in HD patient post mortem brain tissue and fibroblast lines Journal of Neurology, Neurosurgery & Psychiatry. 87: A10.2-A10. DOI: 10.1136/Jnnp-2016-314597.35  0.354
2016 Farshim PP, Deverman BE, Bates GP. L3 Systemic administration of a novel AAV variant results in widespread and efficient gene transfer in R6/2 mice Journal of Neurology, Neurosurgery & Psychiatry. 87: A91.1-A91. DOI: 10.1136/Jnnp-2016-314597.258  0.367
2015 McCourt AC, O'Donovan KL, Ekblad E, Sand E, Craufurd D, Rosser A, Sanders D, Stoy N, Rickards H, Wierup N, Bates GP, Björkqvist M, Quarrell O. Characterization of Gastric Mucosa Biopsies Reveals Alterations in Huntington's Disease. Plos Currents. 7. PMID 26581667 DOI: 10.1371/Currents.Hd.858B4Cc7F235Df068387E9C20C436A79  0.332
2015 Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington's disease. The Lancet. Neurology. 14: 1135-42. PMID 26466780 DOI: 10.1016/S1474-4422(15)00177-5  0.389
2015 Stroedicke M, Bounab Y, Strempel N, Klockmeier K, Yigit S, Friedrich RP, Chaurasia G, Li S, Hesse F, Riechers SP, Russ J, Nicoletti C, Boeddrich A, Wiglenda T, Haenig C, ... ... Bates GP, et al. Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Research. 25: 701-13. PMID 25908449 DOI: 10.1101/Gr.182444.114  0.357
2015 Mielcarek M, Toczek M, Smeets CJ, Franklin SA, Bondulich MK, Jolinon N, Muller T, Ahmed M, Dick JR, Piotrowska I, Greensmith L, Smolenski RT, Bates GP. HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy. Plos Genetics. 11: e1005021. PMID 25748626 DOI: 10.1371/Journal.Pgen.1005021  0.336
2014 Träger U, Andre R, Magnusson-Lind A, Miller JR, Connolly C, Weiss A, Grueninger S, Silajdži? E, Smith DL, Leavitt BR, Bates GP, Björkqvist M, Tabrizi SJ. Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiology of Disease. 73: 388-398. PMID 25447230 DOI: 10.1016/j.nbd.2014.10.012  0.371
2014 Mielcarek M, Bondulich MK, Inuabasi L, Franklin SA, Muller T, Bates GP. The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model. Plos One. 9: e108961. PMID 25268775 DOI: 10.1371/journal.pone.0108961  0.388
2014 Corrochano S, Renna M, Osborne G, Carter S, Stewart M, May J, Bates GP, Brown SD, Rubinsztein DC, Acevedo-Arozena A. Reducing Igf-1r levels leads to paradoxical and sexually dimorphic effects in HD mice. Plos One. 9: e105595. PMID 25140802 DOI: 10.1371/journal.pone.0105595  0.345
2014 Mielcarek M, Inuabasi L, Bondulich MK, Muller T, Osborne GF, Franklin SA, Smith DL, Neueder A, Rosinski J, Rattray I, Protti A, Bates GP. Dysfunction of the CNS-heart axis in mouse models of Huntington's disease. Plos Genetics. 10: e1004550. PMID 25101683 DOI: 10.1371/Journal.Pgen.1004550  0.404
2014 Beaumont V, Park L, Rassoulpour A, Dijkman U, Heikkinen T, Lehtimaki K, Kontkanen O, Al Nackkash R, Bates GP, Gleyzes M, Steidl E, Ramboz S, Murphy C, Beconi MG, Dominguez C, et al. The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease. Plos Currents. 6. PMID 24558637 DOI: 10.1371/currents.hd.3304e87e460b4bb0dc519a29f4deccca  0.379
2014 Carnemolla A, Labbadia JP, Lazell H, Neueder A, Moussaoui S, Bates GP. Contesting the dogma of an age-related heat shock response impairment: implications for cardiac-specific age-related disorders. Human Molecular Genetics. 23: 3641-56. PMID 24556212 DOI: 10.1093/hmg/ddu073  0.307
2014 Träger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, McKinnon C, Sirinathsinghji E, Kahlon S, Pfister EL, Moser R, Hummerich H, Antoniou M, Bates GP, Luthi-Carter R, et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain : a Journal of Neurology. 137: 819-33. PMID 24459107 DOI: 10.1093/brain/awt355  0.389
2014 Schipper-Krom S, Juenemann K, Jansen AH, Wiemhoefer A, van den Nieuwendijk R, Smith DL, Hink MA, Bates GP, Overkleeft H, Ovaa H, Reits E. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies. Febs Letters. 588: 151-9. PMID 24291262 DOI: 10.1016/J.Febslet.2013.11.023  0.362
2014 Mielcarek M, Inuabasi L, Bondulich M, Muller T, Osborne G, Franklin S, Smith D, Neuder A, Rosinski J, Rattray I, Protti A, Bates G. B44 The Cns-heart Axis Is A Source Of Cardiac Dysfunction In Mouse Models Of Huntington's Disease Journal of Neurology, Neurosurgery & Psychiatry. 85: A24-A24. DOI: 10.1136/Jnnp-2014-309032.72  0.372
2013 Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, Modo M. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease. Plos One. 8: e84726. PMID 24367693 DOI: 10.1371/journal.pone.0084726  0.386
2013 Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Osborne GF, Wadel K, Touller C, Butler R, Robertson J, Franklin SA, Smith DL, Park L, Marks PA, ... ... Bates GP, et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. Plos Biology. 11: e1001717. PMID 24302884 DOI: 10.1371/Journal.Pbio.1001717  0.382
2013 Mielcarek M, Seredenina T, Stokes MP, Osborne GF, Landles C, Inuabasi L, Franklin SA, Silva JC, Luthi-Carter R, Beaumont V, Bates GP. HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo. Plos One. 8: e80849. PMID 24278330 DOI: 10.1371/journal.pone.0080849  0.312
2013 Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A, Troncosco J, Ross CA, Bates GP, Krainc D, Sadri-Vakili G, et al. Targeting H3K4 trimethylation in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 110: E3027-36. PMID 23872847 DOI: 10.1073/Pnas.1311323110  0.395
2013 O'Rourke JG, Gareau JR, Ochaba J, Song W, Raskó T, Reverter D, Lee J, Monteys AM, Pallos J, Mee L, Vashishtha M, Apostol BL, Nicholson TP, Illes K, Zhu YZ, ... ... Bates GP, et al. SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Reports. 4: 362-75. PMID 23871671 DOI: 10.1016/J.Celrep.2013.06.034  0.355
2013 Rattray I, Smith E, Gale R, Matsumoto K, Bates GP, Modo M. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD. Plos One. 8: e60012. PMID 23593159 DOI: 10.1371/journal.pone.0060012  0.38
2013 Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, Detloff PJ, Housman DE, Bates GP. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 110: 2366-70. PMID 23341618 DOI: 10.1073/Pnas.1221891110  0.401
2013 Horne EA, Coy J, Swinney K, Fung S, Cherry AE, Marrs WR, Naydenov AV, Lin YH, Sun X, Keene CD, Grouzmann E, Muchowski P, Bates GP, Mackie K, Stella N. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. The European Journal of Neuroscience. 37: 429-40. PMID 23167744 DOI: 10.1111/Ejn.12045  0.363
2012 Weiss A, Träger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. The Journal of Clinical Investigation. 122: 3731-6. PMID 22996692 DOI: 10.1172/Jci64565  0.393
2012 Marcellin D, Abramowski D, Young D, Richter J, Weiss A, Marcel A, Maassen J, Kauffmann M, Bibel M, Shimshek DR, Faull RL, Bates GP, Kuhn RR, Van der Putten PH, Schmid P, et al. Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. Plos One. 7: e44457. PMID 22984513 DOI: 10.1371/journal.pone.0044457  0.373
2012 Beconi M, Aziz O, Matthews K, Moumné L, O'Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, et al. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. Plos One. 7: e44498. PMID 22973455 DOI: 10.1371/journal.pone.0044498  0.339
2012 Landles C, Weiss A, Franklin S, Howland D, Bates G. Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease. Plos Currents. 4: e4fd085bfc9973. PMID 22919566 DOI: 10.1371/4fd085bfc9973  0.418
2012 El-Akabawy G, Rattray I, Johansson SM, Gale R, Bates G, Modo M. Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease. Bmc Neuroscience. 13: 97. PMID 22876937 DOI: 10.1186/1471-2202-13-97  0.355
2012 Bobrowska A, Donmez G, Weiss A, Guarente L, Bates G. SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. Plos One. 7: e34805. PMID 22511966 DOI: 10.1371/Journal.Pone.0034805  0.425
2012 Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, Bates GP, Cheetham ME. Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain : a Journal of Neurology. 135: 1180-96. PMID 22396390 DOI: 10.1093/brain/aws022  0.417
2012 Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, Lo DC, Semmelroth M, Zivanovic A, Abramowski D, Smith D, Lotz GP, Bates GP, Weiss A. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chemistry & Biology. 19: 264-75. PMID 22365609 DOI: 10.1016/j.chembiol.2011.12.020  0.416
2012 Moumné L, Campbell K, Howland D, Ouyang Y, Bates GP. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. Plos One. 7: e31080. PMID 22347433 DOI: 10.1371/journal.pone.0031080  0.383
2012 Träger U, André R, Lahiri N, Magnusson A, Pfister E, Weiss A, Grüninger S, Antoniou M, Bates G, Muchowski P, Björkqvist M, Ostroff G, Aronin N, Tabrizi S. B23 Immune dysfunction in HD human myeloid cells is caused by NFκB pathway dysregulation and is reversed by lowering HTT levels Journal of Neurology, Neurosurgery & Psychiatry. 83: A12.3-A13. DOI: 10.1136/Jnnp-2012-303524.39  0.333
2012 Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Wadel K, Touller C, Butler R, Robertson J, Franklin S, Smith D, Park L, Marks P, Wanker E, ... ... Bates G, et al. A12 HDAC4 interacts with huntington and HDAC4 reduction decreases cytoplamsic aggregation and rescues synaptic dysfunction in HD mouse models Journal of Neurology, Neurosurgery, and Psychiatry. 83. DOI: 10.1136/Jnnp-2012-303524.12  0.391
2011 Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. Plos One. 6: e27746. PMID 22140466 DOI: 10.1371/journal.pone.0027746  0.677
2011 Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, Seredenina T, Woodman B, Moussaoui S, Frentzel S, Luthi-Carter R, Paganetti P, Bates GP. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. The Journal of Clinical Investigation. 121: 3306-19. PMID 21785217 DOI: 10.1172/JCI57413  0.41
2011 van der Burg JM, Winqvist A, Aziz NA, Maat-Schieman ML, Roos RA, Bates GP, Brundin P, Björkqvist M, Wierup N. Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice. Neurobiology of Disease. 44: 1-8. PMID 21624468 DOI: 10.1016/J.Nbd.2011.05.006  0.361
2011 Taylor DM, Balabadra U, Xiang Z, Woodman B, Meade S, Amore A, Maxwell MM, Reeves S, Bates GP, Luthi-Carter R, Lowden PA, Kazantsev AG. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. Acs Chemical Biology. 6: 540-6. PMID 21370928 DOI: 10.1021/cb100376q  0.338
2011 Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. The Journal of Clinical Investigation. 121: 476-83. PMID 21285520 DOI: 10.1172/JCI45364  0.362
2010 Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell MM, Reeves SA, Bates GP, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 107: 7927-32. PMID 20378838 DOI: 10.1073/Pnas.1002924107  0.372
2010 Crittenden JR, Dunn DE, Merali FI, Woodman B, Yim M, Borkowska AE, Frosch MP, Bates GP, Housman DE, Lo DC, Graybiel AM. CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease. Human Molecular Genetics. 19: 1756-65. PMID 20147317 DOI: 10.1093/Hmg/Ddq055  0.438
2010 Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. The Journal of Biological Chemistry. 285: 8808-23. PMID 20086007 DOI: 10.1074/Jbc.M109.075028  0.387
2010 Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, Finkbeiner S, Paganetti P, Muchowski PJ, Wilson S, Bates GP. Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Human Molecular Genetics. 19: 65-78. PMID 19825844 DOI: 10.1093/Hmg/Ddp467  0.394
2010 André R, Schure U, Magnusson A, Lahiri N, Smith D, Lowdell MW, Bates G, Bjorkqvist M, Tabrizi SJ. A17 Myeloid cell function in mouse models of Huntington's disease Journal of Neurology, Neurosurgery & Psychiatry. 81: A5.4-A6. DOI: 10.1136/jnnp.2010.222570.17  0.344
2010 Taylor D, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith D, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell M, Reeves S, Bates G, Néri C, et al. A10 SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis Journal of Neurology, Neurosurgery, and Psychiatry. 81. DOI: 10.1136/Jnnp.2010.222570.10  0.365
2009 Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, ... ... Bates G, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. The Journal of Cell Biology. 187: 1083-99. PMID 20026656 DOI: 10.1083/Jcb.200909067  0.379
2009 Bett JS, Benn CL, Ryu KY, Kopito RR, Bates GP. The polyubiquitin Ubc gene modulates histone H2A monoubiquitylation in the R6/2 mouse model of Huntington's disease. Journal of Cellular and Molecular Medicine. 13: 2645-57. PMID 19602042 DOI: 10.1111/j.1582-4934.2008.00543.x  0.677
2009 Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, Mielcarek M, Woodman B, Bates GP. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. Plos One. 4: e5747. PMID 19484127 DOI: 10.1371/journal.pone.0005747  0.677
2009 Bett JS, Cook C, Petrucelli L, Bates GP. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. Plos One. 4: e5128. PMID 19352500 DOI: 10.1371/Journal.Pone.0005128  0.424
2009 Zabel C, Mao L, Woodman B, Rohe M, Wacker MA, Kläre Y, Koppelstätter A, Nebrich G, Klein O, Grams S, Strand A, Luthi-Carter R, Hartl D, Klose J, Bates GP. A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. Molecular & Cellular Proteomics : McP. 8: 720-34. PMID 19043139 DOI: 10.1074/mcp.M800277-MCP200  0.375
2009 Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes. 58: 318-28. PMID 18984744 DOI: 10.2337/Db08-0799  0.419
2008 Benn CL, Fox H, Bates GP. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. Molecular Neurodegeneration. 3: 17. PMID 18954449 DOI: 10.1186/1750-1326-3-17  0.703
2008 Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, ... ... Bates GP, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of Experimental Medicine. 205: 1869-77. PMID 18625748 DOI: 10.1084/Jem.20080178  0.713
2008 Gonitel R, Moffitt H, Sathasivam K, Woodman B, Detloff PJ, Faull RL, Bates GP. DNA instability in postmitotic neurons. Proceedings of the National Academy of Sciences of the United States of America. 105: 3467-72. PMID 18299573 DOI: 10.1073/Pnas.0800048105  0.337
2008 Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Régulier E, Bates GP, Paganetti P. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. Journal of Neurochemistry. 104: 846-58. PMID 17986219 DOI: 10.1111/j.1471-4159.2007.05032.x  0.415
2008 van der Burg JM, Bacos K, Wood NI, Lindqvist A, Wierup N, Woodman B, Wamsteeker JI, Smith R, Deierborg T, Kuhar MJ, Bates GP, Mulder H, Erlanson-Albertsson C, Morton AJ, Brundin P, et al. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease. 29: 41-51. PMID 17920283 DOI: 10.1016/J.Nbd.2007.07.029  0.322
2008 Wild EJ, Björkqvist M, Thiele J, Silvestroni A, Soulet D, Magnusson A, Benn CL, Woodman B, André R, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, ... Bates GP, et al. P3-377: A novel pathogenic pathway of immune activation detectable before cinical onset in Huntington's disease Alzheimer's & Dementia. 4: T632-T632. DOI: 10.1016/J.Jalz.2008.05.1947  0.699
2007 Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR. Global changes to the ubiquitin system in Huntington's disease. Nature. 448: 704-8. PMID 17687326 DOI: 10.1038/nature06022  0.438
2007 Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. Journal of Proteome Research. 6: 2833-40. PMID 17552550 DOI: 10.1021/Pr0700753  0.365
2007 Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, ... ... Bates GP, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/Hmg/Ddm133  0.419
2007 Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, Wells DJ, Latchman DS, de Belleroche J, Tabrizi SJ, Morimoto RI, Bates GP. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. Human Molecular Genetics. 16: 1078-90. PMID 17360721 DOI: 10.1093/Hmg/Ddm057  0.369
2007 Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, Moffitt H, Sathasivam K, Bates GP. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Research Bulletin. 72: 83-97. PMID 17352931 DOI: 10.1016/j.brainresbull.2006.11.004  0.395
2006 Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease. 23: 190-7. PMID 16697652 DOI: 10.1016/J.Nbd.2006.02.011  0.376
2006 Björkqvist M, Petersén A, Bacos K, Isaacs J, Norlén P, Gil J, Popovic N, Sundler F, Bates GP, Tabrizi SJ, Brundin P, Mulder H. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Human Molecular Genetics. 15: 1713-21. PMID 16613897 DOI: 10.1093/Hmg/Ddl094  0.377
2006 Tsang TM, Woodman B, McLoughlin GA, Griffin JL, Tabrizi SJ, Bates GP, Holmes E. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. Journal of Proteome Research. 5: 483-92. PMID 16512662 DOI: 10.1021/pr050244o  0.368
2006 Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Human Molecular Genetics. 15: 33-44. PMID 16311253 DOI: 10.1093/Hmg/Ddi423  0.408
2006 Hockly E, Tse J, Barker AL, Moolman DL, Beunard JL, Revington AP, Holt K, Sunshine S, Moffitt H, Sathasivam K, Woodman B, Wanker EE, Lowden PA, Bates GP. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiology of Disease. 21: 228-36. PMID 16111888 DOI: 10.1016/j.nbd.2005.07.007  0.395
2005 Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Current Opinion in Neurology. 18: 698-705. PMID 16280682 DOI: 10.1097/01.wco.0000186842.51129.cb  0.343
2005 Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, Mariotti C, Di Donato S, Corsini A, Bates G, Pruss R, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 9932-9. PMID 16251441 DOI: 10.1523/Jneurosci.3355-05.2005  0.399
2005 Papalexi E, Persson A, Björkqvist M, Petersén A, Woodman B, Bates GP, Sundler F, Mulder H, Brundin P, Popovic N. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. The European Journal of Neuroscience. 22: 1541-6. PMID 16190907 DOI: 10.1111/J.1460-9568.2005.04324.X  0.351
2005 Benn CL, Landles C, Li H, Strand AD, Woodman B, Sathasivam K, Li SH, Ghazi-Noori S, Hockly E, Faruque SM, Cha JH, Sharpe PT, Olson JM, Li XJ, Bates GP. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Human Molecular Genetics. 14: 3065-78. PMID 16183657 DOI: 10.1093/Hmg/Ddi340  0.727
2005 Smith R, Petersén A, Bates GP, Brundin P, Li JY. Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction. Neurobiology of Disease. 20: 673-84. PMID 15967669 DOI: 10.1016/J.Nbd.2005.05.008  0.365
2005 Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, Messer A. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiology of Disease. 19: 47-56. PMID 15837560 DOI: 10.1016/J.Nbd.2004.11.003  0.366
2005 Cornett J, Cao F, Wang CE, Ross CA, Bates GP, Li SH, Li XJ. Polyglutamine expansion of huntingtin impairs its nuclear export. Nature Genetics. 37: 198-204. PMID 15654337 DOI: 10.1038/Ng1503  0.337
2005 Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America. 102: 892-7. PMID 15642944 DOI: 10.1073/pnas.0408936102  0.391
2004 Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith DL, Woodman B, Bates GP. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Human Molecular Genetics. 13: 1389-405. PMID 15115766 DOI: 10.1093/Hmg/Ddh144  0.396
2003 Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, Young AB, Standaert DG, Thompson LM, Cha JH. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiology of Disease. 14: 624-36. PMID 14678777 DOI: 10.1016/j.nbd.2003.08.024  0.302
2003 Gourfinkel-An I, Parain K, Hartmann A, Mangiarini L, Brice A, Bates G, Hirsch EC. Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice. Journal of Neurochemistry. 86: 1369-1378. PMID 12950446 DOI: 10.1046/J.1471-4159.2003.01916.X  0.404
2003 Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA, Bates GP, Hockly E. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Annals of Neurology. 54: 186-96. PMID 12891671 DOI: 10.1002/ana.10614  0.394
2003 Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, ... Bates GP, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 100: 2041-6. PMID 12576549 DOI: 10.1073/pnas.0437870100  0.387
2002 Zabel C, Chamrad DC, Priller J, Woodman B, Meyer HE, Bates GP, Klose J. Alterations in the mouse and human proteome caused by Huntington's disease. Molecular & Cellular Proteomics : McP. 1: 366-75. PMID 12118078 DOI: 10.1074/Mcp.M200016-Mcp200  0.399
2002 Peters PJ, Ning K, Palacios F, Boshans RL, Kazantsev A, Thompson LM, Woodman B, Bates GP, D'Souza-Schorey C. Arfaptin 2 regulates the aggregation of mutant huntingtin protein. Nature Cell Biology. 4: 240-5. PMID 11854752 DOI: 10.1038/Ncb761  0.387
2002 Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Annals of Neurology. 51: 235-42. PMID 11835380 DOI: 10.1002/Ana.10094  0.423
2001 Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiology of Disease. 8: 1017-26. PMID 11741397 DOI: 10.1006/nbdi.2001.0438  0.379
2001 Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, Bates GP. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Human Molecular Genetics. 10: 2425-35. PMID 11689489 DOI: 10.1093/Hmg/10.21.2425  0.402
2001 Kusakabe M, Mangiarini L, Laywell ED, Bates GP, Yoshiki A, Hiraiwa N, Inoue J, Steindler DA. Loss of cortical and thalamic neuronal tenascin-C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene. The Journal of Comparative Neurology. 430: 485-500. PMID 11169482 DOI: 10.1002/1096-9861(20010219)430:4<485::Aid-Cne1045>3.0.Co;2-6  0.381
2000 Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 97: 8093-7. PMID 10869421 DOI: 10.1073/pnas.110078997  0.394
2000 Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proceedings of the National Academy of Sciences of the United States of America. 97: 6763-8. PMID 10823891 DOI: 10.1073/pnas.100110097  0.363
2000 Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AHV. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse Annals of Neurology. 47: 80-86. DOI: 10.1002/1531-8249(200001)47:1<80::AID-ANA13>3.0.CO;2-K  0.417
1999 Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 10428-37. PMID 10575040 DOI: 10.1523/Jneurosci.19-23-10428.1999  0.371
1999 Davies SW, Sathasivam K, Hobbs C, Doherty P, Mangiarini L, Scherzinger E, Wanker EE, Bates GP. Detection of polyglutamine aggregation in mouse models. Methods in Enzymology. 309: 687-701. PMID 10507055 DOI: 10.1016/S0076-6879(99)09045-X  0.384
1999 Cha JH, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, Penney JB, Davies SW, Bates GP, Young AB. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 981-9. PMID 10434296 DOI: 10.1098/Rstb.1999.0449  0.349
1999 Davies SW, Turmaine M, Cozens BA, Raza AS, Mahal A, Mangiarini L, Bates GP. From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 981-9. PMID 10434295 DOI: 10.1098/Rstb.1999.0448  0.432
1999 Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies SW, Bates GP. Transgenic models of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 963-9. PMID 10434294 DOI: 10.1098/Rstb.1999.0447  0.409
1999 Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Human Molecular Genetics. 8: 1227-36. PMID 10369868 DOI: 10.1093/Hmg/8.7.1227  0.361
1999 Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker EE, Doherty P, Davies SW, Bates GP. Formation of polyglutamine inclusions in non-CNS tissue. Human Molecular Genetics. 8: 813-22. PMID 10196370 DOI: 10.1093/Hmg/8.5.813  0.41
1999 Reynolds GP, Dalton CF, Tillery CL, Mangiarini L, Davies SW, Bates GP. Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. Journal of Neurochemistry. 72: 1773-6. PMID 10098889 DOI: 10.1046/j.1471-4159.1999.721773.x  0.406
1999 Mangiarini L, Sathasivam K, Bates GP. Molecular pathology of Huntington's disease: Animal models and nuclear mechanisms Neuroscientist. 5: 383-391. DOI: 10.1177/107385849900500613  0.409
1998 Dunnett SB, Carter RJ, Watts C, Torres EM, Mahal A, Mangiarini L, Bates G, Morton AJ. Striatal transplantation in a transgenic mouse model of Huntington's disease. Experimental Neurology. 154: 31-40. PMID 9875265 DOI: 10.1006/Exnr.1998.6926  0.361
1998 Bates GP, Mangiarini L, Davies SW. Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathology (Zurich, Switzerland). 8: 699-714. PMID 9804379 DOI: 10.1111/J.1750-3639.1998.Tb00196.X  0.421
1998 Bates GP, Mangiarini L, Wanker EE, Davies SW. Polyglutamine expansion and Huntington's disease. Biochemical Society Transactions. 26: 471-5. PMID 9765898 DOI: 10.1042/Bst0260471  0.365
1998 Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiology of Disease. 4: 387-97. PMID 9666478 DOI: 10.1006/Nbdi.1998.0168  0.379
1998 Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proceedings of the National Academy of Sciences of the United States of America. 95: 6480-5. PMID 9600992 DOI: 10.1073/pnas.95.11.6480  0.332
1998 Bertaux F, Sharp AH, Ross CA, Lehrach H, Bates GP, Wanker E. HAP1-huntingtin interactions do not contribute to the molecular pathology in Huntington's disease transgenic mice. Febs Letters. 426: 229-32. PMID 9599014 DOI: 10.1016/S0014-5793(98)00352-4  0.406
1998 Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, Callen DF, Gribouval O, Broyer M, Bates GP, van't Hoff W, Antignac C. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nature Genetics. 18: 319-24. PMID 9537412 DOI: 10.1038/ng0498-319  0.301
1998 Davies SW, Beardsall K, Turmaine M, DiFiglia M, Aronin N, Bates GP. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet (London, England). 351: 131-3. PMID 9439509 DOI: 10.1016/S0140-6736(97)08360-8  0.381
1997 Bates GP, Davies SW. Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions. Molecular Medicine Today. 3: 508-15. PMID 9430787 DOI: 10.1016/S1357-4310(97)01142-8  0.383
1997 Sathasivam K, Baxendale S, Mangiarini L, Bertaux F, Hetherington C, Kanazawa I, Lehrach H, Bates GP. Aberrant processing of the Fugu HD (FrHD) mRNA in mouse cells and in transgenic mice. Human Molecular Genetics. 6: 2141-9. PMID 9328479 DOI: 10.1093/Hmg/6.12.2141  0.351
1997 DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (New York, N.Y.). 277: 1990-3. PMID 9302293 DOI: 10.1126/Science.277.5334.1990  0.393
1997 Bates GP, Mangiarini L, Mahal A, Davies SW. Transgenic models of Huntington's disease. Human Molecular Genetics. 6: 1633-7. PMID 9300654 DOI: 10.1093/hmg/6.10.1633  0.412
1997 Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90: 537-48. PMID 9267033 DOI: 10.1016/S0092-8674(00)80513-9  0.409
1997 Sathasivam K, Amaechi I, Mangiarini L, Bates G. Identification of an HD patient with a (CAG)180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage. Human Genetics. 99: 692-5. PMID 9150744 DOI: 10.1007/s004390050432  0.396
1997 Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nature Genetics. 15: 197-200. PMID 9020849 DOI: 10.1038/Ng0297-197  0.418
1996 Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87: 493-506. PMID 8898202 DOI: 10.1016/S0092-8674(00)81369-0  0.396
1994 Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somatic Cell and Molecular Genetics. 20: 27-38. PMID 8197474 DOI: 10.1007/Bf02257483  0.406
1993 MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B, Anderson MA, Wexler NS, Gusella JF, ... Bates GP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell. 72: 971-983. PMID 8458085 DOI: 10.1016/0092-8674(93)90585-E  0.362
1992 MacDonald ME, Novelletto A, Lin C, Tagle D, Barnes G, Bates G, Taylor S, Allitto B, Altherr M, Myers R. The Huntington's disease candidate region exhibits many different haplotypes. Nature Genetics. 1: 99-103. PMID 1302016 DOI: 10.1038/Ng0592-99  0.361
Show low-probability matches.